Cargando…
Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection
The present review summarizes the beneficial and detrimental roles of reactive oxygen species in myocardial ischemia/reperfusion injury and cardioprotection. In the first part, the continued need for cardioprotection beyond that by rapid reperfusion of acute myocardial infarction is emphasized. Then...
Autores principales: | Heusch, Gerd, Andreadou, Ioanna, Bell, Robert, Bertero, Edoardo, Botker, Hans-Erik, Davidson, Sean M., Downey, James, Eaton, Philip, Ferdinandy, Peter, Gersh, Bernard J., Giacca, Mauro, Hausenloy, Derek J., Ibanez, Borja, Krieg, Thomas, Maack, Christoph, Schulz, Rainer, Sellke, Frank, Shah, Ajay M., Thiele, Holger, Yellon, Derek M., Di Lisa, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590874/ https://www.ncbi.nlm.nih.gov/pubmed/37839355 http://dx.doi.org/10.1016/j.redox.2023.102894 |
Ejemplares similares
-
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
por: Lecour, Sandrine, et al.
Publicado: (2021) -
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning
por: Ferdinandy, Péter, et al.
Publicado: (2023) -
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations
por: Hausenloy, Derek J., et al.
Publicado: (2010) -
Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection
por: Bøtker, Hans Erik, et al.
Publicado: (2018) -
Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?
por: Kleinbongard, Petra, et al.
Publicado: (2020)